Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
BriaCell Therapeutics ( (TSE:BCT) ) just unveiled an update.
BriaCell Therapeutics announced updated Phase 2 survival data for its lead immunotherapy candidate, Bria-IMT, in combination with an immune checkpoint inhibitor, showing a significant survival advantage in heavily pretreated metastatic breast cancer patient subtypes. The data revealed that Bria-IMT demonstrated a median overall survival of 13.9 months in triple negative breast cancer and 17.3 months in hormone receptor-positive breast cancer, surpassing the performance of Trodelvy and single-agent chemotherapy, highlighting the potential clinical impact of BriaCell’s novel immunotherapy.
The most recent analyst rating on (TSE:BCT) stock is a Buy with a C$32.00 price target. To see the full list of analyst forecasts on BriaCell Therapeutics stock, see the TSE:BCT Stock Forecast page.
Spark’s Take on TSE:BCT Stock
According to Spark, TipRanks’ AI Analyst, TSE:BCT is a Neutral.
BriaCell Therapeutics has a challenging financial position with no revenue and consistent losses, heavily impacting its stock score. Despite this, recent corporate developments in cancer treatment provide some potential upside. Technical indicators are mixed, and valuation concerns persist with a negative P/E ratio. The company’s reliance on external financing is a notable risk.
To see Spark’s full report on TSE:BCT stock, click here.
More about BriaCell Therapeutics
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care.
Average Trading Volume: 20,527
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$19.31M
For a thorough assessment of BCT stock, go to TipRanks’ Stock Analysis page.